Literature DB >> 2849118

Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency.

C Rooney1, N Taylor, J Countryman, H Jenson, J Kolman, G Miller.   

Abstract

A defective Epstein-Barr virus (EBV) containing a deleted and rearranged genome (het DNA) causes latent EBV to replicate. This activity maps to the 2.7-kilobase-pair WZhet fragment. The BZLF1 open reading frame, present within WZhet as well as in the standard viral BamHI Z fragment, encodes the protein ZEBRA, which induces viral replication. Using gene transfers into Burkitt lymphoma cells, we now demonstrate that rearranged sequences juxtaposed to BZLF1 in het DNA facilitate expression of ZEBRA protein. Two stretches of EBV sequences within a palindromic region of het DNA contain positive regulatory elements. One set, derived from the viral large internal repeat, is newly positioned upstream of BZLF1; the second set is downstream of BZLF1 in het DNA. The capacity of defective HR-1 viruses to disrupt latency of the standard EBV genome is due to abnormal regulation of the BZLF1 gene as a result of genomic rearrangements.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2849118      PMCID: PMC282869          DOI: 10.1073/pnas.85.24.9801

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Polymorphisms of the region of the Epstein-Barr virus genome which disrupts latency.

Authors:  H B Jenson; G Miller
Journal:  Virology       Date:  1988-08       Impact factor: 3.616

2.  Tumor initiators and promoters in the induction of Epstein-Barr virus.

Authors:  H zur Hausen; G W Bornkamm; R Schmidt; E Hecker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

3.  Epstein-Barr virus RNA. VIII. Viral RNA in permissively infected B95-8 cells.

Authors:  M Hummel; E Kieff
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

4.  Epstein-Barr virus with heterogeneous DNA disrupts latency.

Authors:  G Miller; M Rabson; L Heston
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

5.  Structure of defective DNA molecules in Epstein-Barr virus preparations from P3HR-1 cells.

Authors:  M S Cho; G W Bornkamm; H zur Hausen
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

6.  Identification of Epstein-Barr nuclear antigen polypeptide in mouse and monkey cells after gene transfer with a cloned 2.9-kilobase-pair subfragment of the genome.

Authors:  D K Fischer; M F Robert; D Shedd; W P Summers; J E Robinson; J Wolak; J E Stefano; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

7.  Non-immortalizing P3J-HR-1 Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye.

Authors:  M Rabson; L Gradoville; L Heston; G Miller
Journal:  J Virol       Date:  1982-12       Impact factor: 5.103

8.  An unusually high-titer human anti-Epstein Barr virus (EBV) serum and its use in the study of EBV-specific proteins synthesized in vitro and in vivo.

Authors:  C M Edson; L K Cohen; W Henle; J L Strominger
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

9.  Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells.

Authors:  M Rabson; L Heston; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

10.  Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus.

Authors:  M R Lerner; N C Andrews; G Miller; J A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

View more
  52 in total

1.  Marked variation in the size of genomic plasmids among members of a family of related Epstein-Barr viruses.

Authors:  J L Kolman; C J Kolman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

2.  Transcriptional synergy by the Epstein-Barr virus transactivator ZEBRA.

Authors:  M Carey; J Kolman; D A Katz; L Gradoville; L Barberis; G Miller
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

3.  The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular Sp1 transcription factor.

Authors:  S Zalani; E A Holley-Guthrie; D E Gutsch; S C Kenney
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

4.  Epstein-Barr virus BZLF1 protein binds to mitotic chromosomes.

Authors:  Amy L Adamson
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

5.  Marked variation in response of consensus binding elements for the Rta protein of Epstein-Barr virus.

Authors:  Lee-Wen Chen; Pey-Jium Chang; Henri-Jacques Delecluse; George Miller
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 6.  Epstein-Barr virus infection at mucosal surfaces: detection of genomic variants with altered pathogenic potential.

Authors:  J W Sixbey; P Shirley
Journal:  Springer Semin Immunopathol       Date:  1991

7.  Negative regulation of the BZLF1 promoter of Epstein-Barr virus.

Authors:  E A Montalvo; Y Shi; T E Shenk; A J Levine
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

8.  Efficient transcription of the Epstein-Barr virus immediate-early BZLF1 and BRLF1 genes requires protein synthesis.

Authors:  E K Flemington; A E Goldfeld; S H Speck
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

9.  Two phenylalanines in the C-terminus of Epstein-Barr virus Rta protein reciprocally modulate its DNA binding and transactivation function.

Authors:  Lee-Wen Chen; Vineetha Raghavan; Pey-Jium Chang; Duane Shedd; Lee Heston; Henri-Jacques Delecluse; George Miller
Journal:  Virology       Date:  2009-02-15       Impact factor: 3.616

10.  Points of recombination in Epstein-Barr virus (EBV) strain P3HR-1-derived heterogeneous DNA as indexes to EBV DNA recombinogenic events in vivo.

Authors:  Kazufumi Ikuta; Shamala K Srinivas; Tim Schacker; Jun-ichi Miyagi; Rona S Scott; John W Sixbey
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.